Nanotechnology in pulmonary medicine
Mohammad Doroudian1, Andrew O' Neill2, Ronan Mac Loughlin3
1Department of Medicine, Tallaght University Hospital & Trinity College Dublin, Ireland; Department of Cell and Molecular Sciences, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran.
Current Opinion in Pharmacology
|December 20, 2020
Summary
Nanomedicine offers advanced solutions for diagnosing, treating, and preventing pulmonary diseases, including infectious respiratory illnesses. This field utilizes novel nanoparticle-based therapies and theranostic imaging for improved patient outcomes.
Area of Science:
- Medical nanotechnology
- Pulmonary medicine
- Infectious disease research
Background:
- Nanomedicine is increasingly utilized for diagnosing, treating, and preventing pulmonary diseases.
- It addresses challenges like multidrug resistance, side effects of conventional therapies, and early disease detection.
- Applications extend to emerging infectious respiratory diseases such as SARS-CoV, MERS-CoV, H1N1, and SARS-CoV-2.
Purpose of the Study:
- To provide a historical overview of nanomedicine in respiratory diseases.
- To highlight cutting-edge nanomedicine approaches for pulmonary disease management.
- To discuss advancements in nanoparticle-mediated therapies and theranostic imaging.
Main Methods:
- Review of historical and recent applications of nanomedicine in pulmonary diseases.
- Analysis of nanoparticle-mediated combination therapies.
- Examination of novel targeting systems, stimuli-responsive nanoparticles, and theranostic imaging.
Main Results:
- Nanomedicine shows significant progress in addressing clinical challenges in pulmonary diseases.
- Emerging infectious diseases are being targeted with nanomedicine strategies.
- Advanced approaches like targeted delivery and theranostics are enhancing diagnosis and treatment.
Conclusions:
- Nanomedicine presents a promising frontier for managing a wide spectrum of pulmonary diseases.
- Cutting-edge nanotechnologies offer new avenues for combating respiratory infections and improving treatment efficacy.
- Theranostic imaging and targeted therapies are key advancements for future pulmonary disease care.
